Home  »  Industry   »  CHRS’s Stock Market Puzzle: Piecing Together...

CHRS’s Stock Market Puzzle: Piecing Together 2023’s Performance

A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. This year’s metric has recorded a Price decrease of -37.88%. However, over the past six months, we’ve seen a stronger performance of -22.76%. The price of CHRS fallen by 8.61% over the last 30 days. And in the last five days, it has surged by 0.61%.

Currently, the stock price of Coherus BioSciences Inc. (CHRS) is $4.92. In the most recent trading session, the stock underwent a significant upswing, peaking at $4.97 after opening at $4.79. The stock touched a low of $4.71 before closing at $4.78.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Coherus BioSciences Inc.’s stock market performance has been somewhat irregular. The 1-year high for the company’s stock was recorded at $10.99 on 01/13/23, with the lowest value being $3.60 on 05/31/23.

52-week price history of CHRS Stock

The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Coherus BioSciences Inc.’s current trading price is -55.23% away from its 52-week high, while its distance from the 52-week low is 36.67%. The stock’s price range for this period has been between $3.60 and $10.99. The Healthcare sector company’s shares saw a trading volume of about 20.75 million for the day, which was higher than the average daily volume of 3.27 million over the last three months.

The Connection Between Financial Performance and Market Capitalization

Coherus BioSciences Inc. (CHRS) has experienced a quarterly decline of -8.72% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 508.48M and boasts a workforce of 294 employees.

Expert Opinions: Analysts’ Ratings for Coherus BioSciences Inc.

As of right now, 5 analysts are rating Coherus BioSciences Inc. as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.

How Moving Averages and Trading Volume Data Work Together

Based on Barchart.com data, the company’s moving average over the 100-day period was 4.96, with a change in price of -3.14. Similarly, Coherus BioSciences Inc. recorded 3,296,885 in trading volume during the last 100 days, posting a change of -38.96%.

CHRS Stock Stochastic Average

As of today, the raw stochastic average of Coherus BioSciences Inc. over the last 50 days is at 62.80%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 56.22%. Further, the company’s Stochastic %K and %D values for the last 20 days were 46.05% and 50.60%, respectively.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts